Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06171152 · ClinicalTrials.gov registry record · Early Phase 1
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
A Early Phase 1 study of Obesity and Multiple Sclerosis, sponsored by University of Chicago.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06171152: Recruiting Early Phase 1 study of Obesity and Multiple Sclerosis, sponsored by University of Chicago.
NCT06171152 is a Early Phase 1 study of Obesity and Multiple Sclerosis that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 30 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06171152, a Early Phase 1 study of Obesity and Multiple Sclerosis, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making decisions that affect everyday life. By doing this study, researchers hope to learn how liraglutide (Saxenda®), a weight loss drug, affects levels of a certain disease marker in the body called Brain Derived Neurotrophic Factor (BDNF). Participation in this research will last about 21 weeks.
Conditions Studied
Interventions
- DRUG Liraglutide Pen Injector [Saxenda]
- OTHER Medication Diary
Study Locations (1)
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-01-26 |
| Est. Completion | 2026-10-01 |
| Phase | Early Phase 1 |
What NCT06171152 shows while recruiting
NCT06171152 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower).
The record links to 7 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Liraglutide Pen Injector [Saxenda] is the first listed.
NCT06171152 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06171152 about?
NCT06171152 is a clinical study titled "Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues". This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making decisions that affect everyday life. By doing this study, researchers hop...
What is the current status of trial NCT06171152?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2024-01-26. Estimated completion is 2026-10-01.
What conditions does trial NCT06171152 study?
This clinical trial studies the following conditions: Obesity, Multiple Sclerosis, Long COVID, Obese, Obesity, Morbid.
What interventions are being tested in trial NCT06171152?
The interventions under investigation include: Liraglutide Pen Injector [Saxenda] (DRUG), Medication Diary (OTHER).
Who is sponsoring clinical trial NCT06171152?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06171152 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06171152's enrollment target sits among peer trials
30 851st of 1053 higher than 173 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation
RECRUITING · Early Phase 1
-
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
RECRUITING · Early Phase 1
-
Social Determinants of Sleep and Obesity
RECRUITING · Early Phase 1
-
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
RECRUITING · Early Phase 1
-
Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
RECRUITING · Early Phase 1
-
Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI